Pangaea Data launches AI platform to accelerate guideline concordance and ease the pressure on global health systems

• Unveiled at HLTH USA 2025, Pangaea’s AI-driven platform brings together its proven capabilities into a single platform that fits into systems and workflows clinicians already trust 
• It emulates clinical reasoning to flag care gaps, spot untreated and sub-optimally treated patients, automate follow-up and review records like a clinician would, but at scale
• Pangaea’s capabilities are being deployed across health systems in 13 countries focused on prevalent and rare diseases including Chronic Kidney Disease (CKD), Chronic Obstructive Pulmonary Disease (COPD), Asthma, Breast Cancer, Cancer Cachexia, Systemic Lupus Erythematosus (SLE) and Hypophosphatasia (HPP)

South San Francisco, CA, USA; London, UK; October 20: AI health pioneer, Pangaea Data (Pangaea) today launched its next-generation platform, designed to help clinicians close care gaps, find untreated and sub-optimally treated patients and drive real improvement in patient outcomes, all with reduced costs and increased revenues for health systems. 

Pangaea’s platform uses proven capabilities – already being deployed across 13 countries – to flag patients who are missed for appropriate screening or treatments, despite relevant data being present in their records. This not only enables earlier diagnosis and more effective triaging of hard-to-diagnose conditions, but it helps health systems deliver more efficient care for better patient outcomes. 

Clinical reasoning, scaled

Built to emulate clinical reasoning, the platform reviews patient conversations and medical records as a clinician would, but at scale. It analyzes both structured and unstructured data to identify missed diagnosis, treatment delays, incomplete referrals and other care gaps often hidden in spite of information in the patient’s records.

Powered by advanced AI tools, the platform not only interprets all available patient information but also reasons to provide critical findings, for example, detecting care that is not concordant with established clinical guidelines. It integrates seamlessly with ambient listening tools, to capture further insights from consultations in real time. From there, the platform recommends or even automates next steps, such as scheduling follow-ups, thereby helping clinicians to act proactively without adding administrative burden.

By flagging these care gaps, based on guideline-driven insights, the platform enables earlier intervention, improving both patient outcomes and the overall care experience.

“We don’t just look at data, we bring the patient and their story to life,” said Dr Vibhor Gupta, Founder and CEO of Pangaea Data. “Patients who are at risk usually have their data in the system already, but what’s missing is a platform that sees the full picture and delivers the right insights, at the right time. By prioritizing what matters most, at the moment it matters, Pangaea empowers clinicians to act with confidence and specificity, avoid the alert fatigue so common with existing systems, and do all of this without adding to their workload.” 

Built to work where care happens

Pangaea’s platform is fully embedded into existing electronic health records (EHR) systems, scheduling and referral tools, letting clinicians view the intelligence associated with care gaps identified by Pangaea in the context of a patient’s journey. This means healthcare providers no longer need to jump between systems or manage separate dashboards and can take action to close gaps securely without any disruption to care. 

A win-win for all

Health systems are able to adopt Pangaea’s platform with minimal financial risk because Pangaea works with pharmaceutical sponsors across multiple conditions, enabling a low-cost entry point for health systems. This collaborative approach offers health systems an opportunity to leverage real-time AI at the point of care and for population health purposes.

Pangaea’s capabilities are already in use across prevalent and rare diseases such as Chronic Kidney Disease (CKD), Chronic Obstructive Pulmonary Disease (COPD), Cancer Cachexia, and rare conditions like Hypophosphatasia (HPP). The platform is demonstrating success at identifying untreated and sub-optimally treated patients across these conditions. For example, it found patients at risk of CKD with 97% sensitivity and 85% precision and COPD patients at high risk of exacerbations with 99% sensitivity and 85% precision. 

The platform also found six times more cancer patients who were undiagnosed for cachexia and therefore were not on appropriate treatments in spite of information in their records. This demonstrable performance is helping to halve the cost of treatment for each cachectic cancer patient from £10,000 to £5,000 through earlier intervention. Identifying patients for treatment earlier leads to other benefits for health systems, including faster referrals, improving pre-authorizations, faster treatment initiation - all leading to lower healthcare burden and improved patient outcomes.

Pangaea will be showcasing its platform at the upcoming ESMO conference in Berlin, Germany from 18th - 19th October and HLTH USA 2025 in Las Vegas, Nevada, USA between October 19th-22nd. Additional features and expanded functionality are expected to roll out in late 2025 and early 2026.

ENDS

About Pangaea Data

Pangaea Data is a South San Francisco and London-based company. Pangaea provides an AI-driven platform, which is being deployed across health systems in 13 countries to help clinicians close care gaps by finding untreated and under-treated patients based on existing guidelines, who are missed despite relevant data being present in their medical records. This ensures patients receive timely, guideline-concordant treatment and care and is fostering sustainable, privacy-compliant collaborations between health systems and pharmaceutical companies. Pangaea’s platform has shown improvement in patient outcomes combined with reduced costs (through early diagnosis, effective triaging) and increased revenues (through improved pre-authorizations and treatments) in a sustainable and compliant manner. 

Pangaea Data’s platform is designed to be deployed on the health system’s infrastructure, behind their firewall, ensuring privacy compliance. Furthermore, the platform seamlessly integrates with existing electronic health record (EHR) systems, ambient listening tools and scheduling systems, avoiding disruption to existing clinical or IT workflows.

Pangaea Data’s founders, Dr. Vibhor Gupta and Prof. Yike Guo, have more than 20 years of academic and industry experience and have raised over $300 million in academic research funding. Their advisors and investors include industry veterans, such as Lord David Prior (Former Chairman, NHS England) and Mr. Andy Palmer (Former Head of Systems Integration, Novartis). For more information, visit www.pangaeadata.ai